Last reviewed · How we verify

NCT03877861

Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms

Completed Last updated 9 June 2021
What this trial tests

trial testing Readiband Sleep Tracking in Glioma in 7 participants. Completed in 1 May 2021.

Timeline
15 March 2018
Primary endpoint
1 May 2021
1 May 2021

Quick facts

Lead sponsorAllina Health System
StatusCompleted
Study typeOBSERVATIONAL
Enrollment7
Start date15 March 2018
Primary completion1 May 2021
Estimated completion1 May 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Allina Health System — full company profile →

Who can join

Adults 22 to 70, any sex, with Glioma or Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study will assess feasibility and to obtain initial estimates of efficacy of Sleep Activity and Task Effectiveness (SAFTE) model, which can accurately estimate the impact of scheduling factors and sleep history on both safety and productivity. The SAFTE model will be used to asses cancer-related fatigue and study potential associations of change in sleep patterns to tumor recurrence in patients with high grade glioma. Data will be collected using the Readiband™ Sleep Tracker (https://www.fatiguescience.com/sleep-science-technology/). The Readiband device captures high-resolution sleep data, validated against the clinical gold standard of polysomnography with 92% accuracy. Sleep data is transmitted to the cloud automatically for SAFTE Fatigue Model analysis. We will correlate clinical progression data obtained from the patient's electronic medical record with SAFTE data.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Glioma

Currently open trials in the same condition.

Other Allina Health System trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03877861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing